Recent Updates
Recently added Catalysts
VKTX Positive Sentiment

VANQUISH-1: Phase 3 Trial with Enrollment of a Diverse Population to Test Efficacy of Subcutaneous VK2735 in Adult Participants with Obesity or Overweight With Weight-Related Comorbidity

Monday, May 11, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: VKTX has initiated the VANQUISH-1 Phase 3 trial to evaluate the efficacy of VK2735 in adults with obesity or overweight conditions and related comorbidities. The trial aims to enroll a diverse population, enhancing the relevance of the findings. This represents a significant step in VKTX's efforts to address obesity-related health issues.
Price reaction · baseline $31.72 (2026-05-11 close) · hit after-hours · 2 other VKTX headline(s) in the window, move may be shared
day 0 close · peak
-1.3%

Market Sentiment Analysis

POSITIVE FACTORS

  • Enrollment of a diverse population in the trial
  • Testing VK2735 for obesity and weight-related comorbidities
  • Phase 3 trial indicates advanced stage of development

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+53%
120-day peak, hindsight
Typical move
13.6%
average across 5 past catalysts
Cash runway
~11 mo
Medium dilution risk
Lead asset
VK2735
Phase 3 · Weight Loss

Full Press Release Details

• About Management Board of Directors Careers
• Pipeline Overview VK2735 VK3019 VK2809 VK0214 VK5211 Publications
• Investors Overview Stock Information Stock Chart Historical Price Lookup News & Events Press Releases Webcasts SEC Filings Analyst Coverage Corporate Governance Governance Highlights Mangement Board of Directors Committee Composition Shareholder Services Information Request E-mail Alerts Investor Relations Contacts Corporate Presentation
• Contact
• Management
• Board of Directors
• Careers
• Overview
• VK2735
• VK3019
• VK2809
• VK0214
• VK5211
• Publications
• Overview
• Stock Information Stock Chart Historical Price Lookup
• News & Events Press Releases Webcasts
• SEC Filings
• Analyst Coverage
• Corporate Governance Governance Highlights Mangement Board of Directors Committee Composition
• Shareholder Services Information Request E-mail Alerts Investor Relations Contacts
• Corporate Presentation
• Stock Chart
• Historical Price Lookup
• Press Releases
• Webcasts
• Governance Highlights
• Mangement
• Board of Directors
• Committee Composition
• Information Request
• E-mail Alerts
• Investor Relations Contacts

Frequently Asked Questions

What is the VANQUISH-1 trial?

The VANQUISH-1 trial is a Phase 3 study testing VK2735 for obesity and related comorbidities.

Who is participating in the trial?

The trial aims to enroll a diverse population of adult participants.

What condition does VK2735 target?

VK2735 targets obesity and weight-related health issues.

What stage is VK2735 in its development?

VK2735 is currently in Phase 3 of clinical trials.

ShareAdd on Google
Tags: VKTX Viatris Investor Conferences Healthcare VK2735 obesity weight-related comorbidity clinical trial
Last updated: May 11, 2026

Biotech snapshot

Cash runway
$502M liquidity · $42M/mo burn
~11 mo
Medium dilution risk
Lead asset
VK2735Phase 3
Weight Loss →

Catalyst track record

+53%
best trade around VKTX's most recent catalyst

Peak hindsight return over a 120-day window, across 5 tracked FDA/PDUFA catalysts for VKTX.

See every catalyst's timing & PoA →